Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to “Buy” at G.Research

G.Research upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a hold rating to a buy rating in a research report report published on Wednesday morning, Zacks.com reports. G.Research also issued estimates for Lexicon Pharmaceuticals’ FY2019 earnings at $0.65 EPS, FY2020 earnings at ($1.55) EPS, FY2021 earnings at ($1.10) EPS, FY2022 earnings at ($0.75) EPS and FY2023 earnings at ($0.35) EPS.

LXRX has been the topic of several other research reports. Wedbush reiterated an outperform rating and set a $17.00 price objective (down previously from $35.00) on shares of Lexicon Pharmaceuticals in a report on Thursday, August 1st. Zacks Investment Research cut Lexicon Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, July 3rd. ValuEngine upgraded Lexicon Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, August 1st. BidaskClub cut Lexicon Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, July 19th. Finally, Gabelli upgraded Lexicon Pharmaceuticals from a hold rating to a buy rating and set a $3.00 target price on the stock in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $6.70.

NASDAQ:LXRX opened at $2.34 on Wednesday. Lexicon Pharmaceuticals has a fifty-two week low of $1.13 and a fifty-two week high of $11.51. The business’s 50-day simple moving average is $1.74 and its 200-day simple moving average is $5.01.



Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.13). The firm had revenue of $9.68 million during the quarter, compared to analyst estimates of $28.52 million. During the same quarter in the previous year, the business earned ($0.33) EPS. Lexicon Pharmaceuticals’s quarterly revenue was down 29.9% compared to the same quarter last year. As a group, equities analysts expect that Lexicon Pharmaceuticals will post -0.08 EPS for the current fiscal year.

In other news, CEO Lonnel Coats bought 37,000 shares of the business’s stock in a transaction on Friday, August 16th. The shares were purchased at an average price of $1.35 per share, for a total transaction of $49,950.00. Following the purchase, the chief executive officer now owns 87,695 shares of the company’s stock, valued at approximately $118,388.25. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Sam L. Barker acquired 24,000 shares of the company’s stock in a transaction dated Friday, August 2nd. The shares were bought at an average price of $1.18 per share, for a total transaction of $28,320.00. Following the purchase, the director now owns 40,187 shares in the company, valued at $47,420.66. The disclosure for this purchase can be found here. Insiders acquired a total of 111,000 shares of company stock worth $143,670 in the last 90 days. Company insiders own 6.40% of the company’s stock.

Several institutional investors have recently made changes to their positions in LXRX. BNP Paribas Arbitrage SA raised its stake in shares of Lexicon Pharmaceuticals by 940.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 9,934 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 8,979 shares in the last quarter. Gamco Investors INC. ET AL raised its stake in shares of Lexicon Pharmaceuticals by 10.0% during the 1st quarter. Gamco Investors INC. ET AL now owns 22,000 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 2,000 shares in the last quarter. Wealth & Pension Services Group Inc. acquired a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $60,000. Pictet Asset Management Ltd. increased its holdings in shares of Lexicon Pharmaceuticals by 42.6% during the 1st quarter. Pictet Asset Management Ltd. now owns 586,850 shares of the biopharmaceutical company’s stock worth $3,263,000 after acquiring an additional 175,400 shares during the last quarter. Finally, Pinnacle Associates Ltd. increased its holdings in shares of Lexicon Pharmaceuticals by 1.8% during the 1st quarter. Pinnacle Associates Ltd. now owns 550,549 shares of the biopharmaceutical company’s stock worth $3,061,000 after acquiring an additional 9,615 shares during the last quarter. Institutional investors own 98.88% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Story: Convertible Shares

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.